A detailed history of Pnc Financial Services Group, Inc. transactions in Galapagos Nv stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 74 shares of GLPG stock, worth $2,080. This represents 0.0% of its overall portfolio holdings.

Number of Shares
74
Previous 52 42.31%
Holding current value
$2,080
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$24.2 - $30.67 $532 - $674
22 Added 42.31%
74 $2,000
Q2 2024

Aug 09, 2024

SELL
$24.78 - $32.48 $272 - $357
-11 Reduced 17.46%
52 $1,000
Q1 2024

May 10, 2024

BUY
$32.2 - $42.44 $2,028 - $2,673
63 New
63 $2,000
Q3 2021

Nov 05, 2021

SELL
$52.17 - $70.2 $8,712 - $11,723
-167 Closed
0 $0
Q2 2021

Aug 06, 2021

SELL
$68.86 - $83.34 $12,050 - $14,584
-175 Reduced 51.17%
167 $11,000
Q1 2021

May 07, 2021

BUY
$76.15 - $111.94 $23,530 - $34,589
309 Added 936.36%
342 $26,000
Q4 2020

Feb 12, 2021

SELL
$96.85 - $148.25 $10,169 - $15,566
-105 Reduced 76.09%
33 $3,000
Q3 2020

Nov 06, 2020

SELL
$122.47 - $213.56 $7,715 - $13,454
-63 Reduced 31.34%
138 $19,000
Q2 2020

Aug 07, 2020

BUY
$185.52 - $231.25 $27,085 - $33,762
146 Added 265.45%
201 $39,000
Q1 2020

May 08, 2020

BUY
$143.0 - $274.03 $7,865 - $15,071
55 New
55 $10,000
Q3 2019

Nov 08, 2019

SELL
$130.44 - $187.64 $7,435 - $10,695
-57 Closed
0 $0
Q2 2019

Aug 09, 2019

BUY
$111.45 - $128.93 $6,352 - $7,349
57 New
57 $0
Q3 2018

Nov 09, 2018

SELL
$90.63 - $120.22 $4,531 - $6,011
-50 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$88.4 - $105.34 $4,420 - $5,267
50 New
50 $0
Q1 2018

May 11, 2018

SELL
$94.51 - $120.23 $5,670 - $7,213
-60 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$84.48 - $104.02 $5,068 - $6,241
60
60 $0

Others Institutions Holding GLPG

About GALAPAGOS NV


  • Ticker GLPG
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,835,500
  • Market Cap $1.85B
  • Description
  • Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...
More about GLPG
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.